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REVIEW
The Expanding Landscape of Alternative
Splicing Variation in Human Populations
Eddie Park,1 Zhicheng Pan,2 Zijun Zhang,2 Lan Lin,1 and Yi Xing1,2,*
Alternative splicing is a tightly regulated biological process by which the number of gene products for any given gene can be greatly
expanded. Genomic variants in splicing regulatory sequences can disrupt splicing and cause disease. Recent developments in sequencing
technologies and computational biology have allowed researchers to investigate alternative splicing at an unprecedented scale and res-
olution. Population-scale transcriptome studies have revealed many naturally occurring genetic variants that modulate alternative
splicing and consequently influence phenotypic variability and disease susceptibility in human populations. Innovations in experi-
mental and computational tools such as massively parallel reporter assays and deep learning have enabled the rapid screening of
genomic variants for their causal impacts on splicing. In this review, we describe technological advances that have greatly increased
the speed and scale at which discoveries are made about the genetic variation of alternative splicing. We summarize major findings
from population transcriptomic studies of alternative splicing and discuss the implications of these findings for human genetics and
medicine.Introduction
Pre-mRNA splicing is a conserved biological process in
which introns within nascent RNA molecules are removed
and exons are ligated to form mature mRNA products.1
Through alternative choices of exons and splice sites dur-
ing splicing—a process known as alternative splicing—a
single gene can produce multiple mRNA isoforms that
dramatically diversify the transcriptome and the prote-
ome.2 Although the human genome has only approxi-
mately 20,000 protein-coding genes,3 the unique mRNA
isoforms generated from each gene can be more than ten
times that number.4 Nearly all multi-exon human genes
are alternatively spliced.5,6 The basic patterns of alternative
splicing include exon skipping, alternative 50 and 30 splice
sites, mutually exclusive exons, intron retention, and alter-
native splicing coupled with alternative first or last exons
(Figure 1A). Beyond these basic patterns involving binary
choices of exons or splice sites during splicing, many com-
plex alternative splicing patterns exist in the transcrip-
tome7 (see Figure 1B for examples). In extreme cases, the
combinatorial choices of multiple alternatively spliced re-
gions can generate tens of thousands of mRNA isoforms
from a single gene.8 The resulting mRNA isoforms can
have distinct regulatory properties in the cell, such as local-
ization, stability, and translational efficiency, and can be
translated into stable protein isoforms with divergent
structures and functions.9,10 Therefore, alternative splicing
provides a powerful mechanism for expanding the regula-
tory and functional repertoire of eukaryotic organisms.
Alternative splicing is regulated in a cell-type- and
developmental-stage-specific manner.11 This regulation is
orchestrated through an extensive protein-RNA inter-
action network involving cis elements within the pre-
mRNA and trans-acting factors that bind to these cis1Department of Microbiology, Immunology, & Molecular Genetics, Universit
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 2017 The Authors. This is an open access article under the CC BY-NC-ND lelements12 (Figure 1C). The most conserved cis splicing
elements include the 50 and 30 splice sites that define the
boundary of an intron with its upstream and downstream
exon, respectively, as well as the branch site and polypyri-
midine tract upstream of the 30 splice site. These elements
are recognized by the core splicing machinery (the spliceo-
some) and play an essential role in defining exon and
intron identity.12 In addition to these core elements, auxil-
iary cis elements in exons or flanking introns can act as
splicing enhancer or silencer elements to promote or
repress exon splicing via their interactions with trans-
acting splicing regulators, in particular RNA-binding
proteins (RBPs).13 For example, cell-type-specific splicing
regulators, such as ESRP, CELF, MBNL, RBFOX, and PTB
family members, control the alternative splicing profiles
and cell identities of epithelial, muscle, and neuronal cells
by interacting with their cognate cis elements within the
pre-mRNA to produce cell-type-specific isoforms.11
Alternative splicing is frequently affected by human ge-
netic variants and disease mutations. A large fraction of
human disease mutations disrupt splice site signals or
splicing enhancer or silencer elements within the pre-
mRNA, leading to the production of aberrant mRNA and
protein products.14 It has been estimated that such cis
splicing mutations constitute 15%–60% of human disease
mutations.15 Additionally, mutations disrupting trans-
acting splicing regulators cause a wide spectrum of diseases
by globally compromising the splicing of many down-
stream target genes.16 Through decades of genetic and
medical research, the role of aberrant splicing as a primary
cause of Mendelian diseases has been firmly established
and extensively reviewed.15,17 However, until recently,
much less was known and appreciated about the extent
of naturally occurring alternative splicing variation amongy of California, Los Angeles, Los Angeles, CA 90095, USA; 2Bioinformatics
os Angeles, CA 90095, USA
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Figure 1. A Primer on Alternative
Splicing
(A and B) Basic (A) and complex (B)
patterns of alternative splicing. Dark-
blue boxes represent constitutively spliced
exons. Red, light-blue, and green boxes
represent alternatively spliced exons.
(C) Alternative splicing is regulated by
an extensive protein-RNA interaction
network involving cis elements within
the pre-mRNA and trans-acting factors
that bind to these cis elements. The most
essential splicing signals within the pre-
mRNA are the 50 splice site (50SS), 30 splice
site (30SS), branch site (A), and polypyrimi-
dine tract (Y(n)). The 50 and 30 splice sites
have highly conserved GU and AG dinu-
cleotides as the first and last two nucleo-
tides of the intron, respectively. The U1
snRNP complex recognizes the 50 splice
site, and the U2 snRNP complex recognizes
the branch site. The U2AF proteins recog-
nize the 30 splice site and polypyrimidine
tract. Exonic splicing enhancers (ESEs),
exonic splicing silencers (ESSs), intronic
splicing enhancers (ISEs), and intronic
splicing silencers (ISSs) are pre-mRNA cis
regulatory motifs that recruit various
RNA-binding proteins (e.g., SR and hnRNP
proteins) to regulate alternative splicing.human individuals and how alternative splicing affects
phenotypic variability and disease susceptibility in human
populations.
Recent developments in genomic technologies and
computational tools have enabled transcriptome-wide
studies of alternative splicing at an unprecedented scale
and resolution.5,6 New data depict an expanding landscape
of alternative splicing variation across human tissues and
populations. Here, we describe technological advances that
have markedly increased the speed and scale at which dis-
coveries are made about the genetic variation of alternative
splicing. We review population-scale transcriptome studies
that have revealed alternative splicing to be a primary causal
mechanism underlying genome-wide association study
(GWAS) signals of complex traits and diseases.We highlight
innovative experimental and computational approaches
that enable the rapid discovery and characterization of
genomic variants that alter splicing. Finally, we discuss the
clinical applicationsof thesefindingsaswell as their implica-
tions for future genetic and medical research.
Technologies for High-Throughput Analysis of
Alternative Splicing
The conventional molecular biology approach to the
quantification of alternative splicing is reverse transcrip-12 The American Journal of Human Genetics 102, 11–26, January 4, 2018tion polymerase chain reaction (RT-
PCR).18 In the late 1990s, sequencing
of expressed sequence tags (ESTs),
which are fragments of full-length
mRNAs, revealed widespread alterna-tive splicing in eukaryotic organisms.19 The development
of splicing-sensitive microarrays in the mid-2000s allowed
researchers to examine global splicing regulatory programs
across tissues, cellular states, and species.20 Notably, all
three types of technologies have been used to discover
the association between genotypes and alternative
splicing patterns in human populations.21 However, these
technologies have low throughput (RT-PCR and ESTs),
have high noise (ESTs and splicing microarray), or are
limited to known splicing events (RT-PCR and splicing
microarray).19,20
Powered by high-throughput second-generation DNA
sequencers, the advent of RNA sequencing (RNA-seq) in
the late 2000s transformed many aspects of biomedical
research, including studies of transcriptome complexity
and alternative splicing.22 Because of their massively paral-
lel nature, state-of-the-art high-throughput sequencers are
now able to generate billions of short sequence reads in a
single run.23 Sequencing mRNAs with these sequencers al-
lows the discovery of novel genes and mRNA isoforms, the
estimation of gene expression levels, and the quantitation
of alternative splicing events.22 Three landmark papers
in 2008 demonstrated the use of RNA-seq for character-
izing alternative splicing in mammalian tissues.5,6,24
Since then, RNA-seq has rapidly eclipsed microarray as
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Figure 2. Strengths and Weaknesses of
Short-Read and Long-Read RNA-Seq
(A) Schematic diagram of an alternatively
spliced gene that generates two distinct
mRNA isoforms. The first, middle, and
last exons are constitutive exons. The sec-
ond and fourth exons are alternative
exons. The two alternative exons are co-
spliced such that the long isoform con-
tains all five exons and the short isoform
contains only the first, middle, and last
exons.
(B) Short-read RNA-seq generates many
reads, enabling the accurate quantitation
of individual alternative exons, but the
long-range coupling between the two
alternative exons is lost.
(C) Long-read RNA-seq captures the long-
range coupling between alternative exons
and identifies the correct full-length
mRNA isoforms, but the limited number
of reads reduces the precision of isoform
quantitation.the standard approach for transcriptome profiling.
Currently, RNA-seq data for over 70,000 human samples
have been deposited into public repositories,25 and the
number continues to rise at a rapid pace.
Although typical RNA-seq experiments analyze polyade-
nylated (polyAþ) mRNAs from whole cells or bulk tissue,
the RNA-seq workflow is versatile enough to allow diverse
types of applications that can obtain transcriptome infor-
mation at a more fine-grained level.26 For example, RNA-
seq analysis of non-polyadenylated (polyA) RNAs enables
the discovery and quantitation of polyA non-coding
RNAs, including circular RNAs created by back-splicing
events.27,28 Isolation and sequencing of RNAs from
distinct subcellular fractions have been used for character-
izing the subcellular localization of mRNA isoforms as
well as co-transcriptional splicing of nascent RNAs on
chromatin.29–31 Single-cell RNA-seq has become an
increasingly popular approach to studying the transcrip-
tome, including alternative splicing, at the individual-cell
level.32,33 Finally, although Illumina sequencers generate
only short sequence reads, specialized protocols for library
preparation can be used for inferring full-lengthmRNA iso-
forms with the use of Illumina RNA-seq data. Tilgner et al.
developed a ‘‘synthetic long read’’ RNA-seq approach for
use with Illumina sequencers.34 The principle behind
this method is to generate RNA-seq libraries from a given
sample separated into many small pools. Each pool con-
tains a small number of RNA molecules (approximately
1,000 or fewer), and the assumption is that for most genes,
no more than one molecule per gene is present in each
pool. Then, short reads from each pool can be assembled
into full-length transcripts by de novo sequence assembly
algorithms. Using this approach, the authors identified
novel mRNA isoforms and determined that certain distantThe Amalternatively spliced exons tend to co-occur in full-length
mRNA molecules, whereas others tend to be spliced in a
mutually exclusive manner. A caveat to this approach is
that it is limited by the same issues of de novo assembly
with short reads, primarily mis-assemblies and repetitive
sequences.35 Moreover, the assumption of one RNA mole-
cule per gene in each pool might not hold true for highly
expressed genes.
Ultimately, the interest in sequencing full-length mRNA
transcripts has led to a renaissance of long-read mRNA
sequencing, now using third-generation DNA sequencers
most notably from Pacific Biosciences (PacBio)36 and
Oxford Nanopore Technologies.37 For example, PacBio
isoform sequencing (Iso-Seq) has successfully identified
many novel transcripts and alternative splicing events in
tissues and cell types with well-characterized transcrip-
tomes,38,39 whereas Nanopore RNA-seq has been used for
determining exon connectivity and full-length mRNAs in
complex alternatively spliced genes with thousands of
distinct isoform products.40 The strengths of third-genera-
tion long-read RNA-seq are in their long read lengths,
which allow the direct resolution of isoform structure
and the interrogation of repetitive RNA sequences,
whereas their main weaknesses are their higher error rates
and lower throughput (Figure 2). For the purpose of
analyzing alternative splicing, the higher error rates are
tolerable because aligners can leverage the long read
lengths to align reads to exons and splice junctions. How-
ever, the smaller read number due to the lower throughput
is a major bottleneck for the accurate quantitation of iso-
form abundance. A hybrid approach of combining long,
error-prone reads from third-generation sequencers with
short, accurate reads from second-generation sequencers
has been developed for correcting sequencing errors anderican Journal of Human Genetics 102, 11–26, January 4, 2018 13
obtaining isoform quantitation from long reads.38 From a
historical perspective, the data of third-generation long-
read RNA-seq resemble those of EST sequencing, and
computational methods developed for EST data have
proven useful for PacBio and Nanopore RNA-seq data.41
Beyond sequencing, imaging is emerging as a powerful
technology for transcriptome analysis with spatiotemporal
resolution. Sequential fluorescence in situ hybridization
(seqFISH)42 and multiplexed error-robust fluorescence
in situ hybridization (MERFISH)43 are imaging-based
methods for single-cell transcriptomics and can quantify
hundreds of target transcripts at the single-molecule
level with spatial resolution. These methods integrate sin-
gle-molecule fluorescence in situ hybridization with a
barcoding scheme to distinguish hundreds of transcripts
simultaneously. Each target transcript has a predefined
sequential fluorescent barcode, which is used for identi-
fying the transcript via cycles of hybridization with
different fluorescent probes. Currently, seqFISH and
MERFISH have primarily been applied to gene-level quan-
tification, but with customizable probes, these approaches
are in principle applicable to isoform analysis.
Quantifying Alternative Splicing by Using RNA-Seq Data
Because of the popularity of Illumina RNA-seq, many
computational tools have been developed for estimating
mRNA isoform expression and quantifying alternative
splicing variation with the use of short-read RNA-seq
data.44,45 These tools fall into two broad categories accord-
ing to their strategies for data analysis.
The first category represents transcript-based tools that
seek to estimate the abundances and relative proportions
of full-length mRNA isoforms by using short-read RNA-
seq data. This approach typically involves aligning short
reads to a reference genome or transcriptome and then
estimating the abundances of mRNA isoforms by using
an expectation-maximization algorithm.46,47 Recent in-
novations in pseudo-alignment algorithms have led to
alignment-free RNA-seq transcript quantitation with
significantly improved speed and computational effi-
ciency.48,49 Isoform proportions can then be inferred
from the estimated abundances of all mRNA isoforms of
a given gene. A drawback of the transcript-based approach
is that inferring the abundance of full-length mRNA iso-
forms from short reads is non-trivial, and the results are
sensitive to the choice of transcript annotations.45 More-
over, for genes with multiple alternatively spliced regions,
it is not straightforward to attribute change in the abun-
dance of mRNA isoforms to differential splicing regulation
at specific exons or splice sites.
The second category represents event-based tools that
seek to directly quantify individual alternative splicing
events by using RNA-seq data. In this approach, alterna-
tive splicing events are discovered from RNA-seq data,
reads aligned to specific exons or splice junctions are
counted, and appropriate statistical methods are used for
quantifying alternative splicing and detecting differential14 The American Journal of Human Genetics 102, 11–26, January 4, 2splicing between distinct biological conditions. A widely
used metric in event-based analyses is percent spliced in
(PSI or c), which represents the percentage of a gene’s
mRNA transcripts that include a specific exon or splice
site.50 For a given alternative splicing event, the PSI value
can be calculated from the counts of RNA-seq reads sup-
porting specific exons or splice junctions.50,51 Many popu-
lar computational tools for RNA-seq analysis of alternative
splicing are event based (MISO,50 SpliceTrap,52 rMATS,51
andMAJIQ,7 to name a few). These tools differ in their def-
initions of alternative splicing events (basic versus com-
plex), read-counting procedures, and statistical methods
for quantifying and determining differential alternative
splicing. Nonetheless, for the same set of alternative
splicing events, these tools tend to produce highly concor-
dant PSI estimates.53 Given that the PSI value represents a
proportion estimated from read counts, the confidence
interval of the PSI estimate is dependent on the overall
RNA-seq read coverage for an event of interest, such that
a higher coverage leads to a more reliable PSI estimate.
This is a critical issue in RNA-seq analysis of alternative
splicing, and studies have shown that modeling the confi-
dence interval of PSI values on the basis of RNA-seq read
counts improves downstream statistical inference.50,51,54
Interestingly, a hybrid approach leveraging full-length
transcript quantitation for event-based analysis has
been employed in a tool called SUPPA.53 This tool first
runs alignment-free transcript quantitation software to es-
timate the abundance of mRNA isoforms and then con-
verts these estimates to alternative splicing quantitation
at the event level. With the use of pseudo-alignment algo-
rithms,48,49 this approach is fast and scalable to large data-
sets. However, it is restricted to pre-existing transcript
annotations and cannot discover or quantify novel alter-
native splicing events. This issue is a limitation for
analyzing genetic variation of alternative splicing, given
that genomic variants can generate novel alternative
splicing events in individual transcriptomes.55,56
Computational Approaches for Discovering Genetic
Associations of Alternative Splicing
With the continued increase in capacity and reduction in
cost of high-throughput sequencers, generating RNA-seq
datasets across many individuals in a population has
become feasible (Figure 3A). Such population-scale RNA-
seq datasets enable transcriptome-wide studies to associate
genotypes with alternative splicing variation. Splicing
quantitative trait locus (sQTL) analysis is a commonly
used approach for discovering genetic variants associated
with alternative splicing (Figure 3B).57–59 QTL analyses
involve correlating genotypes with quantifiable pheno-
types (traits). In sQTL analysis, the quantitative profiles
of alternative splicing (e.g., PSI values) are treated as
traits and tested for association with genotypes. Several
computational methods have been developed for
identifying sQTLs from population-scale genotype and
RNA-seq data.57–61 Zhao et al. developed GLiMMPS, a018
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Figure 3. Strategies for Discovering Ge-
netic Associations of Alternative Splicing
(A) A population of individuals is geno-
typed, and their transcriptomes are subject
to RNA-seq.
(B) Splicing quantitative trait locus (sQTL)
analysis. For a given exon, the splicing
level (PSI value) is measured for each
individual on the basis of RNA-seq reads
aligned to distinct mRNA isoforms. The
PSI values are treated as quantitative traits
and tested for association with genotypes
across all individuals for the identification
of significant sQTLs.
(C) Allele-specific alternative splicing
(ASAS) analysis. Splicing levels (PSI values)
are measured in an allele-specific manner
for individuals who are heterozygous for
a given SNP. For each individual, a PSI mea-
surement can be obtained for each allele
on the basis of allele-specific reads aligned
to distinct mRNA isoforms. Reproducible
allelic differences in PSI values across mul-
tiple heterozygous individuals provide evi-
dence for significant ASAS events.computational method that identifies sQTLs at the event
level by associating the PSI values of individual alterna-
tive splicing events with genotypes across the population.
An important feature of GLiMMPS is that it uses a general-
ized linear mixed model to model the confidence interval
of the PSI value in each individual as a function of RNA-
seq coverage, which leads to improved accuracy over
competing statistical models that treat the PSI value as a
point estimate.57 Monlong et al. developed sQTLseekeR,
a computational method that identifies sQTLs at the tran-
script level.59 sQTLseekeR treats the relative abundances of
all alternatively spliced isoforms of a gene as a vector and
uses a distance-based approach to test for association
with genotypes. Because this method is applicable to any
number of isoforms, it can detect sQTLs arising from
both simple and complex alternative splicing events.
Notably, the sQTL approach can be used to test for the as-
sociation between any alternative splicing event and any
SNP in cis or trans.62 cis-sQTL analyses could pinpoint
genetic variants affecting cis splicing regulatory elements.
On the other hand, trans-sQTL analyses can potentially
identify hotspots where a SNP at a single genomic locusThe American Journal of Humanaffects the alternative splicing of
numerous genes across the genome.
Such trans-sQTL hotspots have the
potential to reveal known or novel
regulators of alternative splicing.
Allele-specific alternative splicing
(ASAS) analysis is a complementary
approach to sQTL analysis for discov-
ering genetic variants associated with
alternative splicing (Figure 3C). ASAS
analysis aims to identify differential
alternative splicing between mRNAtranscripts expressed from two haplotypes of an individ-
ual. This approach involves using heterozygous SNPs pre-
sent in mRNAs to assign RNA-seq reads to two alleles and
then testing for differential splicing between the two al-
leles. Such an allele-specific strategy has been applied to
different types of alternative RNA processing mechanisms,
including alternative splicing.63–65 Compared with the
sQTL approach, the ASAS approach is unique in that the
two alleles are exposed to an identical cellular environ-
ment; thus, their splicing differences in the individual
can be attributed to cis genetic effects. However, for the
ASAS approach to work, a heterozygous SNP must be ex-
pressed outside of the alternatively spliced region to enable
allele-specific read assignment while being sufficiently
close to the alternative splicing event to be detected on
the same RNA-seq read with this event. As a result of this
limitation, certain events might not be accessible with
the ASAS approach using short-read RNA-seq data; how-
ever, recent work has explored the use of long-read
RNA-seq for identifying ASAS events.66 In an interesting
extension of the conventional ASAS approach applied to
RNA-seq data of polyAþ mRNAs, Hsiao et al. integratedGenetics 102, 11–26, January 4, 2018 15
Table 1. Population-Scale RNA-Seq Studies of Alternative Splicing Variation in Human Transcriptomes
Study Tissue or Cell Type
Sample
Size Summary
Montgomery et al.68 LCLs 60 one of the first two population-scale transcriptome genetics studies to use RNA-
seq; identified 110 sQTL events in a European population at a 0.01 permutation
threshold
Pickrell et al.69 LCLs 69 one of the first two population-scale transcriptome genetics studies to use RNA-
seq; identified 187 genes with significant sQTLs in an African population at a
10% FDR, andmany of these altered splicing by affecting cis splicing regulatory
elements
Lappalainen et al.64 LCLs 462 the largest population-scale RNA-seq dataset on LCLs; was generated by the
Geuvadis project and included data on four European populations and one
African population; identified 639 genes with trQTLs, where the genotype is
significantly associated with the ratio of individual transcript level to total
gene expression; found that genetic variation of gene expression levels and
transcript isoform structure is equally common but largely controlled by
independent causal variants
Battle et al.62 whole blood 922 whole blood from the Depression Genes and Networks cohort; identified 1,370
genes with significant sQTLs at a 5% FDR; a total of 159 sQTLs were in high LD
with trait- and disease-associated GWAS SNPs; the large sample size also
allowed the identification of candidate trans-sQTLs
Fadista et al.70 pancreatic islets 89 identified 371 sQTLs, including sQTLs in known T2D-associated loci or in
genes associated with beta cell function and glucose metabolism
Li et al.71 LCLs 17 RNA-seq study of a 17-individual, three-generation family; allowed the
discovery of sQTLs controlled by rare variants; identified 261 sQTLs at a 50%
FDR; found that sQTLs with large effects in the family were enriched with rare
variants
GTEx Consortium72 43 tissues 1,641 data from the pilot phase of the GTEx project: 1,641 samples from 43 tissues
across 175 individuals; identified an average of 1,900 and 250 sQTL genes
per tissue with Altrans58 and sQTLseekeR,59 respectively; most sQTL genes were
not eQTL genes; significant sQTLs tended to be shared among tissues, whereas
tissue-specific sQTLs represented only 7%–21% of sQTLs, depending on the
tissue type
Chen et al.73 monocytes, neutrophils,
and T cells
197 CD14þmonocytes, CD16þ neutrophils, and naive CD4þ T cells from up to 197
individuals; quantified splicing by using both PSI event-based measurements
and relative abundances of transcript isoforms; identified over 2,000 genes
with sQTLs at a 5% FDR in each of the three cell types
Pala et al.74 leukocytes 624 included a total of 624 individuals from Sardinia; first sQTL study to integrate
whole-genome and RNA-seq data of multiple families to discover common and
rare variants affecting splicing; identified 6,768 sQTLs
Takata et al.75 brain (prefrontal cortex) 206 identified 1,595 sQTLs in 1,341 unique genes; significant sQTLs were enriched
with disease-associated GWAS loci, particularly loci associated with
schizophrenia
The following abbreviations are used: FDR, false discovery rate; T2D, type 2 diabetes; and trQTL, transcript ratio QTL.ASAS analysis with polyAþ and polyA RNA-seq data for
distinct subcellular compartments (cytosolic and nu-
clear).67 By examining the allelic ratio of RNA-seq reads
from mature cytosolic polyAþ mRNAs or from nuclear
polyA RNAs representing spliced-out products, the au-
thors were able to identify both exonic and intronic vari-
ants affecting alternative splicing.
Widespread Variation and Phenotypic Association of
Alternative Splicing in Human Populations
In the last few years, population-scale RNA-seq datasets
have been generated for diverse tissues and cell types
(Table 1). Many of the initial RNA-seq studies were per-
formed with lymphoblastoid cell lines (LCLs).64,68,69,71,76
LCLs are individual-specific immortalized cell lines created
through the infection of human B cells with Epstein-Barr
virus.77 These cell lines have been extensively character-16 The American Journal of Human Genetics 102, 11–26, January 4, 2ized by large-scale genotyping efforts, such as the
HapMap and 1000 Genomes projects.78,79 Therefore,
they provide readily available materials for studying the
association between genetic variants and gene regulation,
including alternative splicing. In two pioneering studies,
Pickrell et al. and Montgomery et al. performed RNA-seq
of LCLs from African and European populations.68,69
In addition to identifying QTLs affecting overall gene
expression levels (expression QTLs or eQTLs), both studies
discovered over 100 sQTLs. The largest LCL RNA-seq
dataset was generated by the Geuvadis (Genetic European
Variation in Health and Disease) Consortium, which per-
formed RNA-seq on 462 LCL samples from five popula-
tions from the 1000 Genomes Project.64 Amajor limitation
of LCLs, however, is that they represent a single, relatively
homogeneous cell type, whereas transcriptome regulation
is strongly tissue and cell-type specific. More recently,018
population-scale RNA-seq studies have been applied to
different tissues.62,70,72–75 The most comprehensive effort
to date is the GTEx (Genotype-Tissue Expression) Con-
sortium,80,81 which has released raw RNA-seq data along
with whole-genome genotype data for over 10,000 tissue
samples from 53 tissue sites (GTEx release V7), and this
dataset continues to expand. Furthermore, induced plurip-
otent stem cells (iPSCs) are being explored for RNA-seq-
based QTL studies as an alternative to LCLs and tissues.82
Not only would human iPSCs be able to replace LCLs as
a source of individual-specific, continuously expandable
biological materials, but these cells can also be differenti-
ated in vitro into many mature cell types, thus circumvent-
ing the bottleneck of availability and access in tissue-based
RNA-seq studies.
Using these large-scale datasets, researchers have begun
to define the landscape, genetic architecture, and pheno-
typic association of alternative splicing variation in human
populations (Table 1). Despite the differences in tissue
and cell type, sample size, and sequencing depth, as well
as the computational methods used for discovering sQTLs,
several consensuses have emerged. These studies demon-
strate that inheritable genetic variation of alternative
splicing is widespread across diverse human tissues and
cell types. Although sQTL SNPs tend to be enriched at
the essential 50 and 30 splice sites,57,69,72 many sQTLs can
be attributed to SNPs located outside of the splice site re-
gions. These SNPs canmodify splicing enhancer or silencer
elements as well as known RBP binding sites in exonic or
intronic regions.83 The approach of coupling sQTL results
to GWAS signals has identified a large number of sQTLs in
high linkage disequilibrium (LD) with previously identi-
fied GWAS SNPs (Table 1), suggesting that SNPs affecting
alternative splicing could be the causal variants underlying
a substantial fraction of GWAS signals for complex traits
and diseases. For example, an RNA-seq study of 206
human brain (prefrontal cortex) tissues reported signifi-
cant enrichment of sQTLs among GWAS disease loci,
particularly for GWAS SNPs associated with schizo-
phrenia.75 Similarly, an RNA-seq study of 89 pancreatic is-
lets identified sQTLs in known type-2-diabetes-associated
loci.70 One key question is whether sQTLs identified in
these studies are the primary contributors to GWAS-associ-
ated traits and diseases or merely reflect the secondary
effects of SNPs that affect phenotypes via other layers of
gene regulation. To address this question, an elegant study
by Li et al. integrated multiple datasets to analyze eight
types of regulatory QTLs in a cohort of LCLs from an Afri-
can population.84 The authors found that most sQTLs are
independent of eQTLs, and sQTLs appear to have a compa-
rable or even greater magnitude of effects on GWAS traits
than eQTLs. These data suggest that splicing is a primary
link between genetic variation and complex diseases,
consistent with the prevalence of aberrant splicing as a pri-
mary cause of Mendelian diseases.15,17
Two examples of sQTLs that correlate with GWAS signals
are highlighted here. SP140 is a tissue-restricted geneThe Amwith high expression in lymphoid cells,85 and its domain
structure suggests a role in chromatin-mediated regula-
tion of gene expression.86 Several GWASs identified
SP140 SNPs that are significantly associated with chronic
lymphocytic leukemia,87 multiple sclerosis,88 Crohn dis-
ease,89 and inflammatory bowel disease.90 However, the
causal mechanism underlying these GWAS signals re-
mained unknown. On the basis of sQTL analysis of RNA-
seq data of LCLs from a European population, a significant
sQTL signal was found for exon 7 of SP140, and the peak
SNP was a C-to-T exonic SNP, rs28445040 (Figures 4A
and 4B).57 Although this SNP does not alter the encoded
protein sequence of SP140, minigene splicing reporter as-
says demonstrated its role in regulating the splicing level
of SP140 exon 7, such that the T allele is associated with
significantly reduced exon inclusion.57 Because the exon
is 78 bp in length, skipping of this exon would remove
an in-frame 26 amino acid peptide from the protein prod-
uct without affecting the downstream reading frame. Strik-
ingly, this SNP is in high LD with GWAS SNPs of all four
diseases (Figure 4C), suggesting that this is the causal
variant underlying the association between SP140 and
these diseases. Furthermore, the association between this
sQTL and multiple sclerosis was replicated in a recent
case-control study.92 In another example, several studies
identified an sQTL in exon 10 of ERAP2,57,93,94 a gene
encoding a protease that processes antigenic epitopes for
MHC class I antigen presentation.95 An A-to-G intronic
SNP (rs2248374) within the 50 splice site of ERAP2
deactivates the canonical 50 splice site and activates a
downstream cryptic 50 splice site. This change leads to
the production of an aberrant transcript that contains a
premature termination codon subject to nonsense-medi-
ated mRNA decay. RNA-seq data of LCLs indicate a signifi-
cant switch in splicing among different genotypes of
rs2248374, along with a significant change in steady-state
mRNA levels due to alternative-splicing-coupled mRNA
decay (Figures 4D and 4E). The G allele is associated with
lower levels of MHC class I molecules at the surface of
B cells94 and is in LD with GWAS signals for several dis-
eases, such as Crohn disease89 and inflammatory bowel
disease90 (Figure 4F). These two examples are just the tip
of the iceberg for many sQTLs identified across various
studies, and they illustrate that sQTLs can influence com-
plex traits and diseases by altering protein activity and
function (SP140) or mRNA stability and steady-state
mRNA levels (ERAP2). It is also worth noting that the
causal variants for these two GWAS-associated sQTLs are
silent exonic (SP140) or intronic (ERAP2) and would there-
fore be missed by many commonly used tools for variant
annotation.96
Characterizing Causal Variants of Alternative Splicing
via Massively Parallel Reporter Assays
Although RNA-seq can reveal associations between genetic
variants and alternative splicing, identifying the causal
variants underlying the detected associations remains aerican Journal of Human Genetics 102, 11–26, January 4, 2018 17
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Figure 4. Two Examples of sQTLs Associ-
ated with GWAS Signals for Complex
Diseases
(A–C) Alternative splicing of SP140 exon 7
is associated with chronic lymphocytic
leukemia, Crohn disease, inflammatory
bowel disease, and multiple sclerosis. The
alternative splicing event is an exon-skip-
ping event. The C allele is associated with
a higher level of exon inclusion, whereas
the T allele is associated with a higher level
of exon skipping. (A) Boxplot showing
the significant association between SNP
rs28445040 and the splicing level (PSI
value) of SP140 exon 7 within the Geu-
vadis CEU (Utah residents with ancestry
from northern and western Europe) popu-
lation. Each dot represents the PSI value
from a particular individual, and the size
of each dot is proportional to the RNA-seq
read coverage for the alternative splicing
event in that individual. (B) Sashimi plot
indicating the average RNA-seq read den-
sity and splice junction counts for each ge-
notype. Exons and introns are not drawn
to scale, and the relative width of exons
is increased for clarity. (C) LD plot showing
multiple GWAS SNPs (green boxes) linked
with the sQTL SNP (purple box).
(D–F) Alternative splicing of ERAP2 exon
10 is associated with Crohn disease, ulcer-
ative colitis, inflammatory bowel disease,
and birdshot chorioretinopathy. The alter-
native splicing event is an alternative 50
splice site event. The A allele is associated
with a higher level of the upstream canon-
ical 50 splice site, whereas the G allele is
associated with a higher level of the down-
stream cryptic 50 splice site. Usage of the
downstream cryptic 50 splice site intro-
duces a premature stop codon and results
in nonsense-mediated mRNA decay. (D)
Boxplot showing the significant association between SNP rs2248374 and the splicing level (PSI value) of ERAP2 exon 10 (i.e., usage
of the downstream cryptic 50 splice site) within the Geuvadis CEU population. Each dot represents the PSI value from a particular indi-
vidual, and the size of each dot is proportional to the RNA-seq read coverage for the alternative splicing event in that individual. (E)
Sashimi plot indicating the average RNA-seq read density and splice junction counts for each genotype. Exons and introns are not drawn
to scale, and the relative width of exons is increased for clarity. (F) LD plot showing multiple GWAS SNPs (green boxes) linked with the
sQTL SNP (purple box).
RNA-seq data of 89 CEU individuals are from the Geuvadis project.64 Sashimi plots were drawn with rmats2sashimiplot (see Web
Resources). LD plots were drawn with Haploview 4.291 and include CEU individuals from the 1000 Genomes Project (phase 3). For
each boxplot, the top andbottomof the box represent the third andfirst quartiles, respectively. The band in themiddle of the box represents
the median. The whiskers of each boxplot extend to the most extreme data points within 1.5 times the interquartile range from each box.challenging task. In an sQTL analysis, multiple variants
within a haplotype block can be significantly associated
with alternative splicing, but we do not know which vari-
ant(s) causally affect(s) splicing regulation. A widely used
molecular biology approach to the study of splicing regula-
tion is the minigene splicing reporter assay.97 A minigene
splicing reporter is constructed via the insertion of a piece
of genomic DNA that contains the exon of interest and its
flanking intronic sequences into a position where it is
flanked either by exons from another gene (i.e., heterolo-
gous minigene reporter) or by the upstream and
downstream constitutive exons from the same gene
(Figure 5A). Site-directed mutagenesis within a minigene
splicing reporter can be used for assessing the impact of18 The American Journal of Human Genetics 102, 11–26, January 4, 2specific genomic variants or splicing regulatory elements
(Figure 5B). Coupled with high-throughput screens, mini-
gene splicing reporters can be used for identifying splicing
enhancer or silencer elements and discovering trans-acting
factors or small-molecule compounds that regulate the
splicing of specific exons.
With recent advances in oligonucleotide synthesis
technologies and high-throughput sequencing, massively
parallel reporter assays (MPRAs) have become an increas-
ingly popular approach to the study of gene regulation,
including alternative splicing.98 MPRAs test the functional
impacts of many sequence variants in parallel. These se-
quences are inserted into a reporter construct and trans-
fected into cells or combined with cellular extracts for018
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Figure 5. Experimental and Computa-
tional Tools for Characterizing the Causal
Impacts of Genomic Variants on Alterna-
tive Splicing
(A) Schematic diagram of a minigene
splicing reporter. An exon of interest,
along with its flanking intronic se-
quences, is inserted into a splicing reporter
construct, where it is flanked by upstream
and downstream exons containing a pro-
moter and a polyA site. The splicing profile
of the minigene splicing reporter can be
determined by RT-PCR or RNA-seq.
(B) Use of minigene splicing reporters
for characterizing the effects of disease-
causing variants or exonic and intronic
splicing regulatory elements on splicing.
(C) Minigene splicing reporters can be
used in massively parallel reporter assays
(MPRAs) for determining the conse-
quences of many sequence variants on
splicing in a high-throughput manner. A
library of minigenes is transfected into a
cell line, and splicing levels are measured
for all variants simultaneously by RNA-seq.
(D) Deep learning framework for analyzing
alternative splicing. Starting with input
data, including the genome sequence and
RNA-seq data, the framework extracts
genomic and RNA features. These features
include diverse types of quantitative or
qualitative features, such as conservation
score, sequence motifs, secondary struc-
ture, and epigenetic marks. A computa-
tional model is trained to predict splicing
patterns and levels by using the extracted
features. The predictions can be evaluated
with experimental validation (e.g., by
RNA-seq, RT-PCR, or minigene).determining the functional impacts of sequence variants
(Figure 5C). Two recent studies conducted MPRAs with
minigene splicing reporters to determine the effects of cis
sequence variants on splicing.99,100 Rosenberg et al. tested
over two million synthetic minigenes in a high-
throughput fashion.99 Specifically, they created two sepa-
rate libraries to study alternative 50 or 30 splice sites and
analyzed the ability of random sequences to influence
splice site selection. The authors split a single-gene
sequence (Citrine, a derivative of YFP) into two exons as
the backbone of the reporter and inserted introns with
degenerate sequences between the two exons. For the alter-
native 50 splice site library, each intron was designed to
have two competing alternative 50 splice sites, and two
random 25 bp sequences were inserted into positions be-
tween the two competing 50 splice sites or downstream of
the distal 50 splice site. The library for alternative 30 splice
site analysis was designed in the same manner. The result-
ing libraries were transfected into cells, and the splicing
profiles of all sequences were measured in parallel byThe American Journal of HumanRNA-seq. Leveraging the abundant
synthetic reporter data, the authors
were able to use machine learning tomodel splicing patterns and predict the effects of human
SNPs on splicing. Interestingly, the models learned from
alternative 50 and 30 splice sites can also predict exon skip-
ping in vivo. In another study, Soemedi et al. developed a
massively parallel splicing assay (MaPSy) to interrogate
the effects of 4,964 exonic disease-causing mutations on
alternative splicing.100 The authors synthesized a 170 bp
genomic sequence library for all mutant and wild-type
exon pairs. Disease-mutation-containing exons that were
less than or equal to 100 bp in length were selected and
synthesized to include at least 55 bp of the upstream
intron and at least 15 bp of the downstream intron.
Two parallel assays were performed. The first assay tested
the impact of the mutation on the exon’s inclusion or
skipping in vivo when the reporter was transfected into
cells, and the second tested whether the mutation influ-
enced the splicing of the upstream intron in vitro when
the sequence was incubated with nuclear extracts. Even
though they used distinct experimental systems, the two
assays reached general agreement. Approximately 10% ofGenetics 102, 11–26, January 4, 2018 19
the tested disease-causing mutations perturbed splicing in
both assays. By contrast, only 3% of common SNPs per-
turbed splicing in both assays. This 10% is most likely a
lower-bound estimate for the percentage of pathogenic
exonic mutations that disrupt splicing, considering the
cell-type-specific nature of splicing regulation and that
only a single cell type (HEK293) was used for the in vivo
assay.
MPRAs provide a powerful tool for characterizing the
causal genetic variants of alternative splicing. A major
advantage of MPRAs is that these experiments generate
a massive amount of data. As demonstrated by Rosenberg
et al.,99 these data-rich experiments can be coupled with
computational modeling for learning important features
of splicing regulation and predicting the impact of cis
variants on splicing. Additionally, although both studies
performed MPRA experiments in the HEK293 cell line,
these reporters can be transfected into other cell lines
for determining the splicing effects of cis variants in
other cell types. Moreover, MPRAs can be coupled with
sQTL analyses for identifying causal variants underlying
sQTL signals, or they can be utilized in clinical exome
or genome sequencing studies for identifying splicing-
altering variants in disease-affected individuals. One
inherent limitation of MPRAs is that the reporter system
might not completely recapitulate the exact cellular envi-
ronment that allows splicing to occur. For example, fac-
tors such as chromatin states, DNA methylation, and his-
tone marks are known to influence alternative splicing.101
CRISPR-Cas9-based genome editing could address these
issues and has been used in recent work for characterizing
splicing regulatory elements in endogenous genes.102
MPRAs are also limited by the ability to generate libraries;
thus, not all exons or variants are assessable by current
systems. Future improvements in oligonucleotide synthe-
sis technologies could address this limitation and allow a
broader set of exons and deep intronic variants to be
examined.
Alternative Splicing Meets Machine Learning
There has been a long-standing interest in developing in
silico methods of predicting alternative splicing. The basic
scientific premise is that there exists a ‘‘splicing code,’’ a set
of genomic and RNA features and associated rules that
determine the splicing pattern of any primary transcript
in a given cell type.12 Machine learning serves the general
purpose of learning underlying patterns from data to allow
pattern recognition, classification, and prediction. In
computational biology, machine learning has been exten-
sively employed in genomics, transcriptomics, proteomics,
and other domains.103 For example, algorithms have
been developed to predict regulatory elements such as pro-
moters, enhancers, and splice sites.103
Shortly after the EST-based discovery of widespread alter-
native splicing, several studies applied machine learning
methods to predict a binary classification of alternative
versus constitutive exons.104–107 Alternative exons have20 The American Journal of Human Genetics 102, 11–26, January 4, 2distinct sequence features such as exon and intron length,
splice site strength, divisibility by three, sequence conser-
vation within exonic and flanking intronic regions, and
composition of oligonucleotides reflecting splicing regula-
tory elements.107 Machine learning methods can leverage
these features to predict whether an exon undergoes alter-
native splicing.104–107
In a landmark study, Barash et al. used quantitative
splicing microarray data across 27 mouse tissues to pre-
dict tissue-specific patterns of alternative splicing.108
They grouped the 27 tissues into four broad categories
and converted the PSI value of each exon for each tissue
category into three probabilities representing an increase,
a decrease, or no change in exon inclusion in that tissue
category. Then, the authors collected 1,014 features rep-
resenting RNA sequence motifs and transcript features.
They applied a single-layer logistic Bayesian network
that models how individual features cooperate or
compete to influence splicing in each tissue type. Impor-
tantly, the resulting splicing code can reveal novel regu-
latory features and predict mutation-induced changes in
splicing patterns. This work represents a breakthrough
in the field because it was the first demonstration that
in silico models can successfully predict tissue-regulated
alternative splicing. After this work, Xiong et al. added
hidden layers to the Bayesian network to construct a
Bayesian neural network (BNN).109 These hidden layers
helped the authors model non-linear relationships
between features, leading to an improved prediction
accuracy. Based on the BNN framework, the web tool
AVISPA was constructed for splicing prediction and anal-
ysis and was trained with more data and an expanded
feature set.110
Recently, deep learning, a state-of-the-art machine
learning technology, has been applied to predicting alter-
native splicing111–113 (Figure 5D). Deep learning refers to
methods that map raw input feature data to increasingly
abstract feature representations, where higher layers
contain more abstract representations.114 Compared with
canonical machine learning methods, deep learning is
capable of automatically learning complex functions
without a need for handcrafted features or rules, and it
scales well to large and high-dimensional datasets.114,115
Deep learning has been successfully applied in a variety
of fields, including image classification and speech recog-
nition114 and more recently in computational biology.115
In two studies, Frey and colleagues used RNA-seq data
from mouse and human tissues to construct deep learning
models that predict the splicing levels of individual exons
across different tissues111 and the effects of cis genetic
variants on splicing.112 Unlike their previous work
that treated tissue-specific splicing patterns as categorical
data,108 these new methods attempted to predict the nu-
merical PSI values for each exon in each tissue.111,112 Eval-
uations using independent RNA-seq datasets showed good
agreement (R2 ¼ 0.65) between predicted and empirical
PSI values.112 The authors then applied the deep learning018
model to predict the effects of cis genetic variants on RNA
splicing. Their predictions on clinical variants of selected
exons matched well with data from minigene splicing re-
porters. Furthermore, they applied their model to genome
sequencing data of people with autism spectrum disorder
(ASD) and control individuals and predicted misregulated
splicing in 19 candidate genes with ASD-related neuronal
functions. This study demonstrates that deep-learning-
based modeling of splicing provides a powerful tool for
annotating clinical variants and elucidating the genetic
determinants of complex diseases.112 In another inter-
esting application, Huang et al. developed a method called
BRIE, which learns prior information from RNA sequence
features to augment splicing quantification by using sin-
gle-cell RNA-seq data.116
With the rapid accumulation of RNA-seq data and RBP-
RNA interaction maps in the public domain,25,117 future
work should take advantage of more comprehensive
training data and feature space coupled with more
advanced machine learning frameworks to improve in
silico prediction of alternative splicing. As a step in this
direction, Jha et al. recently developed a new deep learning
framework to integrate additional RNA genomics data,
such as CLIP-seq data of RBP-RNA interactions, and RNA-
seq data after the knockdown or overexpression of
RBPs.113 The integrative model generalizes well for RBP
perturbation data and improves the accuracy of alternative
splicing prediction.113 Another interesting direction for
future work is to incorporate chromatin states, epigenetic
marks, and 3D genome organization in a predictive model,
given that splicing is a co-transcriptional process and
these features influence splicing via a variety of molecular
mechanisms.101
In addition to using machine learning techniques to
directly predict splicing patterns and PSI values, other
studies have adopted an alternative strategy of predicting
splicing-altering genomic variants by using prior variant
annotations as training data.118–121 The basic idea is to
collect variants known to affect splicing and/or cause
human diseases along with common ‘‘splicing-neutral’’
variants that are likely to have no effect on splicing
and then build classifiers to distinguish these two cate-
gories of variants. The potential shortcomings of these
approaches are that the classification of positive versus
negative training data might not be accurate and that
the results might suffer from selection bias or overfitting.
Nonetheless, these tools offer a complementary strategy
for evaluating the potential effects of genomic variants
on splicing. An interesting method called ExonImpact
was recently developed to prioritize disease-associated
splicing-altering variants on the basis of the predicted
effects of alternative splicing at the protein level.121
The rationale behind this work is that not all aberrant
splicing events are equally detrimental at the protein
level, and pathogenic splicing mutations have distinct
protein features that can be incorporated into the predic-
tive model.121The AmAlternative Splicing for Disease Diagnosis
Given the importance of splicing in disease pathogenesis
and progression, several therapeutic strategies have
been pursued for correcting splicing defects in disease.17
A notable success is the recent FDA approval of nusinersen,
an antisense oligonucleotide drug for correcting splicing in
spinal muscular atrophy.122
New data are emerging that alternative splicing
might provide diagnostic biomarkers for disease status or
outcome.26 An example of the predictive power of alterna-
tive splicing for disease prognosis was demonstrated in
two recent studies showing that alternative splicing pro-
files can predict cancer patients’ survival time at a compa-
rable and often better accuracy than gene expression
levels.54,123 One possible explanation for these observa-
tions is the intrinsic feature of alternative splicing data.
Given that alternative splicing is quantified as the relative
ratio of multiple isoforms from a single gene, alternative
splicing data are self-normalized on a per-gene basis and
can be viewed as having an ‘‘internal control’’ that could
provide a more robust molecular signature than gene
expression levels, especially for large clinical RNA-seq data-
sets that are prone to technical biases and confounding
issues.54 Consistent with these observations, a new study
reported that alternative-splicing-based classifiers gener-
ally outperform gene-expression-based classifiers for a
wide range of biological classification problems.124
In a major advance with broad implications, Cummings
et al. demonstrated the potential of RNA-seq and alterna-
tive splicing analysis for diagnosing rare diseases.55 The au-
thors analyzed themuscle transcriptomes of 63 individuals
with muscle disorders and compared their RNA-seq data
with GTEx RNA-seq data of 184 control muscle samples.
Of the 63 individuals withmuscle disorders, 50 were genet-
ically undiagnosed. Strikingly, through RNA-seq analysis,
the authors obtained a genetic diagnosis for 35% of the
previously undiagnosed individuals by identifying novel
disease-associated aberrant splicing events in known dis-
ease-associated genes. In four individuals, a recurrent aber-
rant splicing event was discovered in COL6A1, in which a
GC-to-GT genetic variant created a novel 50 splice site,
leading to the exonization of a 72 bp intronic segment
that disrupted the COL6A1 protein product. This variant
would not be easily identifiable by exome or genome
sequencing alone, given that exome sequencing would
miss this deep intronic variant, and genome sequencing
would identify too many variants, making it difficult to
determine their pathogenicity in the absence of RNA-seq
information. Thus, this study offers an important proof
of concept that alternative splicing analysis via the
integration of RNA-seq with exome or genome sequencing
improves disease diagnosis.
Conclusions
The past decade since the advent of RNA-seq has seen
tremendous growth in the amount of human transcriptome
data. Advances in RNA-seq technologies and computationalerican Journal of Human Genetics 102, 11–26, January 4, 2018 21
methods have transformed the study of alternative splicing
in health and disease. Population-scale RNA-seq studies
have discoveredmanynaturally occurring genomic variants
that modulate alternative splicing. Many of these variants
are associated with GWAS signals, suggesting a ubiquitous
contributionofalternative splicing tophenotypicvariability
and disease susceptibility in human populations. These
genetically regulated, GWAS-associated mRNA isoforms
are prime candidates for functional studies of alternative
splicing. Future work using isoform-specific gain-of-func-
tion or loss-of-function assays should elucidate how genetic
variation of alternative splicing affects gene functions and
consequently cellular and organismal phenotypes.
The prevalent role of alternative splicing in Mendelian
and complex diseases suggests that evaluating the impact
of genomic variants on splicing needs to be an integral
part of clinical variant prioritization. Many computa-
tional tools and online resources exist for prioritizing
and annotating variants discovered by exome or genome
sequencing.96 Most tools are designed to predict the
pathogenic effects of missense variants on protein prod-
ucts. However, there is overwhelming evidence that
missense, nonsense, and silent variants within exons,
as well as intronic variants, can disrupt splicing and
cause disease.14 Currently, it is challenging to predict
the pathogenic effects of splicing variants within exonic
and intronic regions, except for variants affecting the
conserved splice site signals, and they are thus ignored
by many commonly used pipelines for variant assess-
ment.96 Recent advances in experimental (e.g., MPRAs)
and computational (e.g., deep learning) tools will allow
researchers and clinicians to screen a large number of var-
iants for their effects on splicing in a systematic and un-
biased manner. Beyond SNPs, other non-SNP variants
such as indels or short tandem repeats can modify cis
splicing regulatory elements and affect alternative
splicing.125,126 The genetic associations between these
non-SNP variants and alternative splicing can also be
discovered and characterized by the computational and
experimental approaches described in this review. A
comprehensive catalog of alternative splicing variation
in human populations, along with the ability to discover
and characterize splicing-altering variants in specific in-
dividuals, holds great value for improving disease diagno-
ses and ultimately patient care in the era of sequencing
and precision medicine.Acknowledgments
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